ArticlePloS one2013
Microbiota and metabolite profiling reveal specific alterations in bacterial community structure and environment in the cystic fibrosis airway during exacerbation.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 1 synthesis or guideline pooled it, 81 citations in OpenAlex.
- Metabolomic Biomarkers to Predict and Diagnose Cystic Fibrosis Pulmonary Exacerbations: A Systematic Review.Frontiers in pediatrics · 2022Pooled it
- Article
- Article
- Practical Guidance for Clinical Microbiology Laboratories: Updated guidance for processing respiratory tract samples from people with cystic fibrosis.Clinical microbiology reviews · 2024Review
- Metabolic specialization drives reduced pathogenicity in Pseudomonas aeruginosa isolates from cystic fibrosis patients.PLoS biology · 2024Article
- The Human Microbiome-A Physiologic Perspective.Comprehensive Physiology · 2024Review
- Does "all disease begin in the gut"? The gut-organ cross talk in the microbiome.Applied microbiology and biotechnology · 2024Review
- How Does Airway Surface Liquid Composition Vary in Different Pulmonary Diseases, and How Can We Use This Knowledge to Model Microbial Infections?Microorganisms · 2024Review
- Mucus Structure, Viscoelastic Properties, and Composition in Chronic Respiratory Diseases.International journal of molecular sciences · 2024Review
- Multiomic Investigations into Lung Health and Disease.Microorganisms · 2023Review
- A comparison of the microbiome composition in lower respiratory tract at different sites in early lung cancer patients.Translational lung cancer research · 2023Article
- Pseudomonas aeruginosa utilizes the host-derived polyamine spermidine to facilitate antimicrobial tolerance.JCI insight · 2022Article
- Exploring the Cystic Fibrosis Lung Microbiome: Making the Most of a Sticky Situation.Journal of the Pediatric Infectious Diseases Society · 2022Review
- Metabolomics of airways disease in cystic fibrosis.Current opinion in pharmacology · 2022Review
- Article
- Network Analysis to Identify Multi-Omic Correlations in the Lower Airways of Children With Cystic Fibrosis.Frontiers in cellular and infection microbiology · 2022Article
- Review
- Lung Microbiome in Cystic Fibrosis.Life (Basel, Switzerland) · 2021Review
- Metabotypes ofMetabolites · 2021Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 2 countries.
Funding
Abstract
Chronic polymicrobial infections of the lung are the foremost cause of morbidity and mortality in cystic fibrosis (CF) patients. The composition of the microbial flora of the airway alters considerably during infection, particularly during patient exacerbation. An understanding of which organisms are growing, their environment and their behaviour in the airway is of importance for designing antibiotic treatment regimes and for patient prognosis. To this end, we have analysed sputum samples taken from separate cohorts of CF and non-CF subjects for metabolites and in parallel, and we have examined both isolated DNA and RNA for the presence of 16S rRNA genes and transcripts by high-throughput sequencing of amplicon or cDNA libraries. This analysis revealed that although the population size of all dominant orders of bacteria as measured by DNA- and RNA- based methods are similar, greater discrepancies are seen with less prevalent organisms, some of which we associated with CF for the first time. Additionally, we identified a strong relationship between the abundance of specific anaerobes and fluctuations in several metabolites including lactate and putrescine during patient exacerbation. This study has hence identified organisms whose occurrence within the CF microbiome has been hitherto unreported and has revealed potential metabolic biomarkers for exacerbation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.